ASH 2021: Investigational Fitusiran Reduces Bleeding Risk in Hemophilia A and B
This prophylactic agent is delivered subcutaneously just once a month
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
This prophylactic agent is delivered subcutaneously just once a month
Only registered members have full access to PracticeUpdate content.